title: CHOROIDAL THICKNESS OF CENTRAL SEROUS CHORIORETINOPATHY SECONDARY TO CORTICOSTEROID USE.
abstract: OBJECTIVE
  Central serous chorioretinopathy (CSC) is a common choroidal disorder which often affects the vision of young adults. Although the molecular mechanisms associated with CSC remain unknown, correlations between steroid hormone use and CSC have been suspected. We investigated the choroidal status of CSC secondary to corticosteroid use.
  
  
  METHODS
  The records of 25 eyes of 25 consecutive acute CSC cases secondary to corticosteroid use were reviewed retrospectively. Central choroidal thickness was measured by optical coherent tomography. Choroidal vessel dilation and choroidal vascular hyperpermeability were evaluated based on indocyanine green angiography findings. The parameters related to secondary CSC were compared with those of 25 eyes of 25 cases with acute idiopathic CSC.
  
  
  RESULTS
  The mean central choroidal thickness of secondary CSC was 294.8 ± 95.0 μm, which was significantly thinner than that of idiopathic CSC (409.4 ± 124.7 μm, P = 0.00064). The proportion of the cases exhibiting choroidal vessel dilation was not significantly different between secondary CSC (52%) and idiopathic CSC (64%). The proportion of cases showing choroidal vascular hyperpermeability was significantly smaller in secondary CSC (62%) than idiopathic CSC (92%) (P = 0.028).
  
  
  CONCLUSIONS
  The choroidal status in the acute phase of secondary CSC after corticosteroid use might be different from that of idiopathic CSC, which suggests a complex mechanism for CSC.
authors: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan.
authors: Shigeru
authors: S
authors: Honda
authors: Akiko
authors: A
authors: Miki
authors: Sentaro
authors: S
authors: Kusuhara
authors: Hisanori
authors: H
authors: Imai
authors: Makoto
authors: M
authors: Nakamura
mesh_terms: D056833:Central Serous Chorioretinopathy / Q000175:diagnosis* / Q000188:drug therapy; D002829:Choroid / Q000187:drug effects* / Q000473:pathology; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods*; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence / Q000379:methods*; D014792:Visual Acuity
chemical_list: D005938:Glucocorticoids